Related Experiment Video
Updated: May 5, 2026

Interview: Glycolipid Antigen Presentation by CD1d and the Therapeutic Potential of NKT cell Activation
Published on: January 1, 2008
Activation or anergy: NKT cells are stunned by alpha-galactosylceramide
Barbara A Sullivan1, Mitchell Kronenberg
1La Jolla Institute for Allergy and Immunology, San Diego, California 92121, USA. mitch@liai.org
Abstract:
Invariant natural killer T (iNKT) cells are T lymphocytes that behave similarly to cells of the innate immune system. The glycolipid alpha-galactosylceramide (alpha-GalCer) is a potent and specific activator of mouse and human iNKT cells and has been used in cancer clinical trials to drive NKT cell-mediated immune responses. However, little is known about the dynamics of the iNKT cell response to alpha-GalCer in vivo. In this issue of the JCI, Parekh and colleagues demonstrate that administration of alpha-GalCer causes iNKT cells to become unresponsive, for at least 1 month, in mice. This leads us to ask, should sequential administration of alpha-GalCer still be used to activate iNKT cells given the anergic state it has been shown here to induce? This intriguing article raises the issue of the avoidance of anergy induction in the design of treatment regimens that use alpha-GalCer as a specific activator of iNKT cells.
Insights
Alpha-galactosylceramide (alpha-GalCer) activates invariant natural killer T (iNKT) cells, but repeated administration can induce a long-lasting unresponsive state in mice. This finding questions the efficacy of sequential alpha-GalCer treatments for immune activation.
Area of Science:
- Immunology
- Cellular Biology
Background:
- Invariant natural killer T (iNKT) cells bridge innate and adaptive immunity.
- Alpha-galactosylceramide (alpha-GalCer) is a specific activator of iNKT cells used in cancer immunotherapy.
- The in vivo dynamics of iNKT cell responses to alpha-GalCer are not well understood.
Discussion:
- Repeated administration of alpha-GalCer induces a profound and sustained anergic state in mouse iNKT cells, lasting at least one month.
- This unresponsiveness challenges the current strategy of sequential alpha-GalCer administration in therapeutic settings.
- Understanding and mitigating alpha-GalCer-induced anergy is crucial for optimizing immunotherapies.
Key Insights:
- Administration of alpha-GalCer leads to a significant and prolonged period of iNKT cell unresponsiveness in vivo.
- The study reveals a critical limitation in using sequential alpha-GalCer doses for immune stimulation.
- This highlights the need to reconsider treatment protocols involving alpha-GalCer.
Outlook:
- Future research should focus on strategies to circumvent or reverse alpha-GalCer-induced anergy.
- Optimizing alpha-GalCer-based immunotherapies requires careful consideration of dosing schedules to avoid immune tolerance.
- This work impacts the design of novel cancer treatments and immunomodulatory strategies.
Related Concept Videos
Activation and Inactivation of G Proteins
GPCR Desensitization
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Cells of the Innate Immune Response
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...

